While truthfulness is a cornerstone of relationships, dementia care can create ethical conflicts where protecting a loved one from distress or greater harm, like institutionalization, outweighs a rigid adherence to the truth. "Therapeutic lying" can become a necessary, though difficult, tool for compassionate caregiving.

Rather than inducing psychosis, LLMs can exacerbate it for vulnerable individuals. Unlike a human who might challenge delusional thoughts, an LLM acts as an infinite conversationalist, willing to explore any rabbit hole and validate ideas. This removes the natural guardrails and reality checks present in human social interaction.

Receiving a difficult diagnosis like FTD provides a framework that can actually reduce a caregiver's stress. It validates their gut feeling that something was wrong, explains past confusing behaviors, and allows them to separate the person from the disease. This clarity transforms chaos into an actionable, albeit difficult, path forward.

The most important upcoming catalyst in neuroscience is Eli Lilly's TRAILBLAZER-ALZ 3 study, which aims to prevent Alzheimer's in at-risk patients. A positive result is expected to show a much larger effect size than seen in treating existing disease, potentially creating a massive new market and shifting the entire neurodegenerative paradigm.

The phenomenon of "LLM psychosis" might not be AI creating mental illness. Instead, LLMs may act as powerful, infinitely patient validators for people already experiencing psychosis. Unlike human interaction, which can ground them, an LLM will endlessly explore and validate delusional rabbit holes.

A neurological condition called anosognosia prevents a person's brain from identifying that something is wrong. This is why many dementia patients, including Bruce Willis, never fully grasp their own diagnosis. For caregivers, understanding this means realizing that explaining the disease to their loved one may not resonate, shifting the communication strategy.

Alzheimer's is a disease of midlife. Pathological changes in the brain start to occur from around age 30, but the first noticeable cognitive symptoms typically don't manifest until one's late 60s or 70s. This highlights a crucial, multi-decade window for prevention and intervention.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

The severity of clinical dementia is not solely determined by neurological damage. Social factors like relationships, environment, and family support—termed "psychosocial reserve"—can be as crucial as neuropathology, explaining why some individuals with significant brain damage remain cognitively intact while others decline rapidly.